Among all 48 participants, the most commonly reported AEs not related to ISRs (≥10%) were upper respiratory tract infection (46%, n = 22; 3/22 had grade 2 events that occurred during the injection phase), pyrexia (21%, n = 10; 4/10 had grade 2 events that occurred 4 to 55 days postinjection and 9/10 had grade 1 events that occurred primarily 2 to 6 days postinjection with the exception of two events that occurred 146 and 338 days postinjection during the follow-up phase), cough (10%, n = 5), headache (10%, n = 5), and increased alanine aminotransferase (ALT) (10%, n = 5). This evidence concerns the gene GPT and Recurrent upper respiratory tract infections.